Economía de la Salud


Opciones: Vista Clásica

Use Monospaced Font
Por defecto enseñar Text Part
Esconda cabeceras de correo

Tema: [<< Primero] [< Prev] [Siguiente >] [Último >>]

Print Responder
Received: by LISTSERV.REDIRIS.ES (LISTSERV-TCP/IP release 16.0) with spool id 11300753 for [log in para visualizar]; Mon, 6 Apr 2020 20:09:45 +0200 from ( []) by (Postfix) with ESMTP id 7EDE9233B8 for <[log in para visualizar]>; Mon, 6 Apr 2020 20:09:45 +0200 (CEST) from ( []) by with SMTP id 036I9iET030686-036I9iEU030686; Mon, 6 Apr 2020 20:09:44 +0200
Content-Type: text/plain; charset="utf-8"
Date: Mon, 6 Apr 2020 20:09:44 +0200
Reply-To: Economía de la Salud <[log in para visualizar]>
Content-Transfer-Encoding: quoted-printable
Emisor: AES ECONSALUD <[log in para visualizar]>
Sender: Economía de la Salud <[log in para visualizar]>
Mime-Version: 1.0
Parts/Attachments: text/plain (6 lines)
Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine 

A COVID-19 vaccine is needed now, but timelines (12-18 months) create large market risk. By the time a vaccine is ready, the crisis may have passed. A CGD Note explores three options: business as usual – which may lead to promotion of an inferior vaccine or fierce country competition for supply – and two models (cost- or value-based), with countries pre-committing to purchases meeting specified efficacy. The authors prefer a value-based model.

Available at: